1. Peptides

SLLK, Control Peptide for TSP1 Inhibitor(TFA) 

Cat. No.: HY-P0301A Purity: 98.80%
Handling Instructions

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

SLLK, Control Peptide for TSP1 Inhibitor(TFA) Chemical Structure

SLLK, Control Peptide for TSP1 Inhibitor(TFA) Chemical Structure

Size Price Stock Quantity
1 mg USD 72 In-stock
Estimated Time of Arrival: December 31
5 mg USD 288 In-stock
Estimated Time of Arrival: December 31
10 mg USD 504 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of SLLK, Control Peptide for TSP1 Inhibitor(TFA):

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

In Vivo

Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice[1].TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). MRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides[2].

Solvent & Solubility
In Vitro: 

H2O : 135 mg/mL (235.36 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7434 mL 8.7169 mL 17.4338 mL
5 mM 0.3487 mL 1.7434 mL 3.4868 mL
10 mM 0.1743 mL 0.8717 mL 1.7434 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Animal Administration
[1]

Mice[1]
The i.p. injection of LSKL, SLLK, or saline began 2 weeks after uninephrectomy and continues thrice weekly for 15 weeks. For the low-dosage treatment regimen, each group of 20 mice receives 3 mg/kg body weight of peptide (LSKL or SLLK) per injection or saline (100 μL/10 g body weight per injection). For the high-dosage treatment regimen, Akita mice are given i.p. injections of LSKL or SLLK peptide at 30 mg/kg body weight per injection or saline (100 μL/10 g body weight per injection)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

573.60

Formula

C₂₃H₄₂F₃N₅O₈

Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SLLK, Control Peptide for TSP1 Inhibitor(TFA)
Cat. No.:
HY-P0301A
Quantity:

SLLK, Control Peptide for TSP1 Inhibitor(TFA)

Cat. No.: HY-P0301A